You can ask your doctor how to safely stop, whether slowly tapering the dose is recommended, and what alternatives might help you maintain results
With these robust findings, CagriSema has the potential to be the first amylin and GLP-1 combination therapy that addresses blood glucose control with reductions in bodyweight for people living with type 2 diabetes." Amylin, a pancreatic hormone co-secreted with insulin in response to food intake, plays a distinct yet complementary role to GLP-1, with potential roles in appetite, glycemic control, bone metabolism, and bodyweight
You may be eligible to participate in this study if you: Are an adult with type 2 diabetes
This medication is not suitable for anyone experiencing diabetic retinopathy
As expected, the Semaglutide group showed significant improvements in key secondary outcomes, including better blood sugar control (lower HbA1c) and reductions in body weight